MELBOURNE, Australia, June 17, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) ("Gelteq" or the "Company"), a biotechnology company developing a proprietary gel-based delivery platform for pharmaceutical, animal health and consumer health applications, today provided a corporate update on recent clinical and commercial milestones toward broader pharmaceutical adoption. Highlights Over the first half of 2026, Gelteq has commenced veterinary and pharmaceutical development programs, expanded its delivery platform, and advanced toward future clinical milestones including: Human clinical trial planning completed and the clinical trial is expected to commence next quarter (beginning July 1, 2026), which is anticipated to advance Gelteq's pharmaceutical program toward a potential FDA regulatory pathway; Veterinary clinical trial commenced for an antiparasitic drug candidate, supporting a planned FDA application targeted for later in 2026 in a global animal health market estimated to exceed US$78 billion1; Preclinical diabetes study commenced, expanding the pharmaceutical pipeline into a major chronic-disease category; Development underway in our research facilities to incorporate peptides and peptide-based therapeutics into stable oral formulations, spanning compounds traditionally delivered by injection and an emerging generation of therapies in development; Signed a strategic debt financing of up to US$3.5 million with an institutional investor to advance our clinical programs and accelerate commercialization; Veterinary palatability trials with Kemin Industries completed, demonstrating strong canine acceptance and confirming Gelteq's ability to mask bitter functional ingredients; Commercial product manufactured for a new customer in the East Asian region, demonstrating Gelteq's ability to formulate, manufacture and deliver at commercial scale; Center of Excellence established in Guangdong Province, China, providing strategic access to one of the world's fastest-growing pharmaceutical ecosystems; and Continued expansion of the active pharmaceutical ingredient (“API”) pipeline across multiple therapeutic categories.
